AUD1.80
2.97% yesterday
Australia, Jun 13, 08:10 am CET
ISIN
AU000000MSB8
Symbol
MSB
Sector
Industry

Mesoblast Stock price

AUD1.80
-0.03 1.37% 1M
-0.05 2.45% 6M
-1.31 42.10% YTD
+0.71 64.68% 1Y
-1.63 47.56% 5Y
-1.94 51.95% 10Y
+1.34 290.30% 20Y
Australia, Closing price Fri, Jun 13 2025
-0.06 2.97%
ISIN
AU000000MSB8
Symbol
MSB
Sector
Industry

Key metrics

Market capitalization AUD2.30b
Enterprise Value AUD2.43b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 280.44
P/S ratio (TTM) P/S ratio 264.84
P/B ratio (TTM) P/B ratio 3.02
Revenue growth (TTM) Revenue growth -24.09%
Revenue (TTM) Revenue AUD8.73m
EBIT (operating result TTM) EBIT AUD-123.50m
Free Cash Flow (TTM) Free Cash Flow AUD-65.79m
Cash position AUD57.99m
EPS (TTM) EPS AUD-0.14
P/E forward negative
P/S forward 77.36
EV/Sales forward 81.92
Show more

Is Mesoblast a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Mesoblast Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Mesoblast forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Mesoblast forecast:

Buy
100%

Financial data from Mesoblast

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
8.73 8.73
24% 24%
100%
- Direct Costs -8.88 -8.88
127% 127%
-102%
18 18
180% 180%
202%
- Selling and Administrative Expenses 45 45
24% 24%
517%
- Research and Development Expense 51 51
30% 30%
588%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -123 -123
45% 45%
-1,415%
Net Profit -159 -159
41% 41%
-1,823%

In millions AUD.

Don't miss a Thing! We will send you all news about Mesoblast directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Silviu Itescu
Employees 73
Founded 2004
Website www.mesoblast.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today